Glenmark Gets Tentative Nod from USFDA for Azelaic Acid Gel

New Delhi: Glenmark Pharmaceuticals today announced receipt of tentative approval from USFDA for its generic version of azelaic acid topical gel used for treating skin inflammation.  Glenmark will market this product upon receiving final approval, it said, adding that the patent for Finacea topical gel, 15 per cent, is scheduled to expire on November 18, 2018.  The tentative nod granted to Glenmark Pharmaceuticals Inc, USA, by the ...